Da Xu1, Yan-Yan Wang1, Xiao-Luan Yan1, Juan Li1, Kun Wang1, Bao-Cai Xing1. 1. Hepatopancreatobiliary Surgery Department I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China.
Abstract
BACKGROUND: Preoperative chemotherapy has widely been used in colorectal cancer liver metastasis (CRLM). Pathological response to chemotherapy is very important in evaluating tumor biology. However, there is still a lack of a non-invasive and accurate method to evaluate pathological response before surgery. METHODS: We retrospectively analyzed the clinicopathologic data of patients with CRLM who underwent liver resection after preoperative chemotherapy between January 2006 and December 2018. Pathological responses were defined as minor when there are ≥50% remnant viable cells and as major when 0-49% remnant viable cells exist. RESULTS: A total of 482 patients were included and randomly divided into training (n=241) and validation (n=241) cohorts. The proportion of major pathologic response was similar between the two groups (51.5% and 48.5%). Multivariate analysis determined the disease-free interval (DFI), tumor size, tumor number, and RAS status as independent predictors of major pathologic response to preoperative chemotherapy. The nomogram incorporating these variables showed good concordance statistics in the training cohort (0.746, 95% CI: 0.685-0.807) and validation cohort (0.764, 95% CI: 0.704-0.823). In addition, the nomogram showed good applicability in patients with different characteristics. CONCLUSIONS: The established nomogram model performed well in predicting pathological response in patients with CRLM. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Preoperative chemotherapy has widely been used in colorectal cancer liver metastasis (CRLM). Pathological response to chemotherapy is very important in evaluating tumor biology. However, there is still a lack of a non-invasive and accurate method to evaluate pathological response before surgery. METHODS: We retrospectively analyzed the clinicopathologic data of patients with CRLM who underwent liver resection after preoperative chemotherapy between January 2006 and December 2018. Pathological responses were defined as minor when there are ≥50% remnant viable cells and as major when 0-49% remnant viable cells exist. RESULTS: A total of 482 patients were included and randomly divided into training (n=241) and validation (n=241) cohorts. The proportion of major pathologic response was similar between the two groups (51.5% and 48.5%). Multivariate analysis determined the disease-free interval (DFI), tumor size, tumor number, and RAS status as independent predictors of major pathologic response to preoperative chemotherapy. The nomogram incorporating these variables showed good concordance statistics in the training cohort (0.746, 95% CI: 0.685-0.807) and validation cohort (0.764, 95% CI: 0.704-0.823). In addition, the nomogram showed good applicability in patients with different characteristics. CONCLUSIONS: The established nomogram model performed well in predicting pathological response in patients with CRLM. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
Colorectal liver metastasis; chemotherapy; pathologic response; predictive model
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: Georgios A Margonis; Neda Amini; Nikolaos Andreatos; Kazunari Sasaki; Jack McVey; Muhammad B Mirza; Samuel Warner; Stefan Buettner; Carlotta Barbon; Jane Wang; Alessandra Pulvirenti; Anastasios Angelou; Carsten Kamphues; Efstathios Antoniou; Emmanouil Pikoulis; Timothy M Pawlik; Klaus Kaczirek; George Poultsides; Doris Wagner; Itaru Endo; Katsunori Imai; Federico Aucejo; Martin E Kreis; Christopher L Wolfgang; Matthew J Weiss Journal: HPB (Oxford) Date: 2019-04-09 Impact factor: 3.647
Authors: L Rubbia-Brandt; E Giostra; C Brezault; A D Roth; A Andres; V Audard; P Sartoretti; B Dousset; P E Majno; O Soubrane; S Chaussade; G Mentha; B Terris Journal: Ann Oncol Date: 2006-10-23 Impact factor: 32.976
Authors: Yun Shin Chun; Jean-Nicolas Vauthey; Piyaporn Boonsirikamchai; Dipen M Maru; Scott Kopetz; Martin Palavecino; Steven A Curley; Eddie K Abdalla; Harmeet Kaur; Chusilp Charnsangavej; Evelyne M Loyer Journal: JAMA Date: 2009-12-02 Impact factor: 56.272
Authors: René Adam; Dennis A Wicherts; Robbert J de Haas; Oriana Ciacio; Francis Lévi; Bernard Paule; Michel Ducreux; Daniel Azoulay; Henri Bismuth; Denis Castaing Journal: J Clin Oncol Date: 2009-03-09 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Dan G Blazer; Yoji Kishi; Dipen M Maru; Scott Kopetz; Yun Shin Chun; Michael J Overman; David Fogelman; Cathy Eng; David Z Chang; Huamin Wang; Daria Zorzi; Dario Ribero; Lee M Ellis; Katrina Y Glover; Robert A Wolff; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: J Clin Oncol Date: 2008-10-20 Impact factor: 44.544
Authors: Giuseppe Zimmitti; Junichi Shindoh; Yoshihiro Mise; Scott Kopetz; Evelyne M Loyer; Andreas Andreou; Amanda B Cooper; Harmeet Kaur; Thomas A Aloia; Dipen M Maru; Jean-Nicolas Vauthey Journal: Ann Surg Oncol Date: 2014-09-17 Impact factor: 5.344